Effects of a Peripheral Nerve Block on Biomarkers of Pain and Inflammation

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00780936
First received: October 24, 2008
Last updated: November 21, 2008
Last verified: November 2008
  Purpose

The purpose of this study is to determine the effect of a local anesthetic nerve block on markers of inflammation and pain after a sunburn. This is important because it may provide information regarding the way that nerve blocks help with the treatment of pain and in particular provide preemptive analgesia.


Condition Intervention
Pain
Procedure: femoral nerve block

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Effect of Peripheral Nerve Block on Inflammatory and Nociceptive Biomarkers in a UV-B Burn Model in Humans

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Measurement of the effect of a preemptive peripheral nerve block on the hyperalgesic response to an artificially induced sunburn.

Secondary Outcome Measures:
  • Measurement of the effect of a preemptive peripheral nerve block on the release of pro-inflammatory cytokines.

Estimated Enrollment: 15
Study Start Date: October 2007
Estimated Study Completion Date: July 2008
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:1. Between 18 and 50 years of age 2. Fluent in English language 3. Provide written informed consent 4. Skin pigmentation type II or III
 Exclusion Criteria:1. Current use of prescription drugs interfering with study objective 2. Use of over-the-counter analgesic/anti-inflammatory drugs within 48h of study participation 3. Current acute or chronic pain conditions 4. Significant medical conditions including psychiatric, neurological, and dermatological diseases 5. Pregnancy 6. Allergies to study drug(s) 7. Concomitant participation in other study protocol

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00780936

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Martin S Angst Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00780936     History of Changes
Other Study ID Numbers: SU-01222008-984, eProtocol number 10740
Study First Received: October 24, 2008
Last Updated: November 21, 2008
Health Authority: USA:Stanford University Panel on Human Subjects

ClinicalTrials.gov processed this record on April 17, 2014